Recombinant proteins for GMP-compatible niche creation to optimize in vitro platelet production for human transfusion
Lead Research Organisation:
University of Cambridge
Department Name: Haematology
Abstract
Each year 250,000 platelet units are transfused to patients in the UK. Platelets are small blood corpuscles that promote blood clotting. In patients with a low platelet count (following cancer therapy, bone marrow transplantation or cardiovascular surgery), there is an increased risk of bleeding (including in the bowels and brain). To prevent this, we currently use transfusion of platelets derived from blood donations. Platelets have a short shelf-life (7 days) because they have are kept at room temperature, which makes stock management a challenge. In addition some patients (in particular women who have had children) can developed an immune reaction that makes "normal" platelets inefficient. For these patients, we use in the UK 15,000 platelet units per year of specially matched platelets (at twice the cost of the usual platelet unit).
The option of producing platelets from banks of stem cells in the laboratory is attractive. It would allow for guaranteed supply, remove the risk of infection transmitted from donor-derived platelets (such as hepatitis viruses, HIV or variant CJD) and allow for better matching of platelets to recipients.
Platelets are produced from megakaryocytes (MKs) in the bone marrow. We have in the last year had a breakthrough in developing an efficient method to produce MKs from stem cells in the laboratory under conditions that are compatible with the production of a product fit for humans. We are now planning to build upon this success in order to produce platelets from these laboratory-grown MKs.
Each MK in the bone marrow produces about 1000 platelets but in the laboratory we only achieve 4 to 7 platelets per MK. This is because MKs only produce platelets efficiently if they are surrounded by the right environment. It is well known that direct contact between MKs and "supportive" cells can enhance platelet production by at least a factor of 10. However these "supportive" cells cannot be used in a system to produce platelets for human use as they are often animal-derived.
We have generated a list of all the proteins that are on the surface of these supportive cells and ranked them according to the likelihood of their effect on platelet production. Four hundred of the top-ranking candidate proteins will be produced in the laboratory. They will be screened in a high-throughput assay (similar to screening for anti-cancer agents) to identify the best combinations of proteins to promote platelet production from MKs. In essence this approach would allow us to replace animal-derived supportive cells with a combination of proteins that have the same positive effect on platelet production but are compatible with a production system for human use.
The best combinations of proteins will be used in a 3-dimensional system that will allow future scaling up of production. We have already generated a collagen-based 3D matrix (in essence an inert porous material very much akin to a sponge) and will be fixing the best candidate proteins onto this "bare" matrix. Cultured MKs will then be seeded upon these "enhanced" scaffolds to assess platelet production. We will use the knowledge generated by this project to seek regulatory approval and further funding for follow-on projects to incorporate these scaffolds in larger scale bioreactors and assess these in vitro produced platelets in human volunteers and patients.
All discoveries will be patented with the view to generate a commercially viable, licenced manufacturing process that will not only benefit health care within the NHS but also contribute to the growth of the UK biomedical technology. This translation will be facilitated by a collaboration with Cell Therapy Catapult, an centrally-funded organization that promotes translation of basic research into cell therapy for patients and by the PI's role in the NHS Blood and Transplant, the organization responsible for the production and distribution of blood products in England.
The option of producing platelets from banks of stem cells in the laboratory is attractive. It would allow for guaranteed supply, remove the risk of infection transmitted from donor-derived platelets (such as hepatitis viruses, HIV or variant CJD) and allow for better matching of platelets to recipients.
Platelets are produced from megakaryocytes (MKs) in the bone marrow. We have in the last year had a breakthrough in developing an efficient method to produce MKs from stem cells in the laboratory under conditions that are compatible with the production of a product fit for humans. We are now planning to build upon this success in order to produce platelets from these laboratory-grown MKs.
Each MK in the bone marrow produces about 1000 platelets but in the laboratory we only achieve 4 to 7 platelets per MK. This is because MKs only produce platelets efficiently if they are surrounded by the right environment. It is well known that direct contact between MKs and "supportive" cells can enhance platelet production by at least a factor of 10. However these "supportive" cells cannot be used in a system to produce platelets for human use as they are often animal-derived.
We have generated a list of all the proteins that are on the surface of these supportive cells and ranked them according to the likelihood of their effect on platelet production. Four hundred of the top-ranking candidate proteins will be produced in the laboratory. They will be screened in a high-throughput assay (similar to screening for anti-cancer agents) to identify the best combinations of proteins to promote platelet production from MKs. In essence this approach would allow us to replace animal-derived supportive cells with a combination of proteins that have the same positive effect on platelet production but are compatible with a production system for human use.
The best combinations of proteins will be used in a 3-dimensional system that will allow future scaling up of production. We have already generated a collagen-based 3D matrix (in essence an inert porous material very much akin to a sponge) and will be fixing the best candidate proteins onto this "bare" matrix. Cultured MKs will then be seeded upon these "enhanced" scaffolds to assess platelet production. We will use the knowledge generated by this project to seek regulatory approval and further funding for follow-on projects to incorporate these scaffolds in larger scale bioreactors and assess these in vitro produced platelets in human volunteers and patients.
All discoveries will be patented with the view to generate a commercially viable, licenced manufacturing process that will not only benefit health care within the NHS but also contribute to the growth of the UK biomedical technology. This translation will be facilitated by a collaboration with Cell Therapy Catapult, an centrally-funded organization that promotes translation of basic research into cell therapy for patients and by the PI's role in the NHS Blood and Transplant, the organization responsible for the production and distribution of blood products in England.
Technical Summary
WP1: Identification of candidate membrane-expressed proteins (MExPs)
The secreted and membrane-tethered proteins for cell lines that support proplatelet (ProPt) formation by MKs in cocultures that promote have been identified from expression arrays and proteomics analysis. The ectodomain of 400 candidate proteins will be cloned into expression vectors by a gene synthesis company.
WP2 Synthesis of recombinant (rec)MExPs.
The recMExPs will be expressed in a mammalian system using the existing infrastructure of Dr Wright's laboratory (Sanger Institute). The recMExPs will be produced in two forms: a soluble pentamer for the initial screening (WP3) and a tagged monomer for immobilization onto a 2D/3D substrates (WP4).
WP3: High throughput screening of candidates recMExPs.
Phase I: ProPlt assay with single recMEXPs: Cultured MKs will be harvested and plated into fibrinogen-coated 96-well plates with pentameric recMExPs. ProPlt formation will be analyzed 48 hours later by means of immunohistochemistry and automated image analysis.
Phase II: ProPlt assay using a combinatorial algorithm: Preliminary data have shown that concurrent recMExPs have a synergistic effect on ProPlt formation. A combinatorial screen of all positive recMExPs identified in Phase I will be carried out using an "overlapping blocks" mathematical model to identify the best combinations of 3 recMExPs.
WP4 Immobilisation of candidate recMExPs onto substrates for niche creation.
WP4 will validate the results obtained in WP3 with non-soluble immobilized forms of the same recMExPs. Monomeric recMExPs with a biotin tag will be immobilized on a plastic surface coated with fibrinogen and streptavidin in equimolar ratios. The ProPlt assay will be carried out on these functionalized plates as described above. We will also determine the range of optimum surface density for each recMExP by ELISA. Finally we will generate appropriately-tagged recMExPs for functionalisation of collagen-based 3D scaffolds.
The secreted and membrane-tethered proteins for cell lines that support proplatelet (ProPt) formation by MKs in cocultures that promote have been identified from expression arrays and proteomics analysis. The ectodomain of 400 candidate proteins will be cloned into expression vectors by a gene synthesis company.
WP2 Synthesis of recombinant (rec)MExPs.
The recMExPs will be expressed in a mammalian system using the existing infrastructure of Dr Wright's laboratory (Sanger Institute). The recMExPs will be produced in two forms: a soluble pentamer for the initial screening (WP3) and a tagged monomer for immobilization onto a 2D/3D substrates (WP4).
WP3: High throughput screening of candidates recMExPs.
Phase I: ProPlt assay with single recMEXPs: Cultured MKs will be harvested and plated into fibrinogen-coated 96-well plates with pentameric recMExPs. ProPlt formation will be analyzed 48 hours later by means of immunohistochemistry and automated image analysis.
Phase II: ProPlt assay using a combinatorial algorithm: Preliminary data have shown that concurrent recMExPs have a synergistic effect on ProPlt formation. A combinatorial screen of all positive recMExPs identified in Phase I will be carried out using an "overlapping blocks" mathematical model to identify the best combinations of 3 recMExPs.
WP4 Immobilisation of candidate recMExPs onto substrates for niche creation.
WP4 will validate the results obtained in WP3 with non-soluble immobilized forms of the same recMExPs. Monomeric recMExPs with a biotin tag will be immobilized on a plastic surface coated with fibrinogen and streptavidin in equimolar ratios. The ProPlt assay will be carried out on these functionalized plates as described above. We will also determine the range of optimum surface density for each recMExP by ELISA. Finally we will generate appropriately-tagged recMExPs for functionalisation of collagen-based 3D scaffolds.
Planned Impact
Each year, 250,000 donor-derived platelet units are produced by the NHS Blood and Transplant at a cost of £58m. Platelets have a short shelf-life of 7 days due to the need to store platelets at room temperature and therefore stock management to guarantee continuous supply is a logistical challenge. Some patients (in particular women who have had multiple pregnancies) develop antibodies against HLA class I epitopes expressed on the platelets which decreases the circulatory half-life (and clinical efficacy) of standard unmatched platelets. Each year, 15,000 HLA-matched platelet units are generated from a recallable panel of typed donors for these patients. Due to the logistics involved, the cost of each pool of HLA-matched platelets is twice that of unmatched platelets. Finally, any human-derived product carries an infectious risk (hepatitis viruses, HIV and prion diseases in particular).
The concept of generating platelets in vitro from a renewable source of stem cells (in this case human pluripotent stem cells, iPSCs) is therefore attractive: 1. guaranteed supply without donor dependence; 2. matching product to patient: 50% of the demand for HLA type I matching amongst the UK population can potentially be covered by 3 cell lines homozygous for one "common" HLA haplotypes and 3. reduction of the risk of transmission of infection. The potential clinical benefit to the NHS and patients of in vitro produced platelets is therefore clear. After the project end, the process will be translated to GMP manufacture (supported by the Cell Therapy Catapult and NHSBT infrastructure) and first-in-man clinical studies on the Cambridge Biomedical Campus where the NHSBT and the lead PI already carry out volunteer studies to assess transfusion products. This offers a clear route for clinical adoption by the NHS.
Regenerative medicine is at the forefront of the strategy for biomedical research in the UK, supported by initiatives such as the Regenerative Medicine Platform (co-funded by the MRC). The University of Cambridge has already formed (together with the University of Sheffield) an RMP hub addressing the issue of derivation and quality control of iPSCs for human use. This would have a direct link to the proposed project. Platelets derived from iPSCs are an ideal exemplar tissue to develop iPSC-based technology in as much as platelets are anucleated and can be irradiated prior to administration to patients, removing potential concerns over tumor growth from iPSCs-derived cellular products. The strategy adopted in this project, aiming at recreating the niche necessary for cell maturation by means of recombinant proteins can be applied to other tissues grown in vitro and therefore discoveries made within this project will benefit the scientific community as a whole, in particular in the field of regenerative medicine. To this end the lead PI has already established a collaboration with the UK RMP Biochemistry of the Niche Hub (Prof S Forbes, Edinburgh) through which distribution to other researchers can be carried out effectively.
Finally one has to consider the potential economic aspect of this work beyond healthcare provision. The business opportunity is the development of a robust manufacturing protocol for the generation of platelets from iPSCs. This will constitute new IP for the project partners, protected through patenting. This will be licenced to blood product manufacturers, such as NHSBT. Beyond the UK, the global market for platelet provision is $300m. Our product is expected to obtain a large share of the market due to advantages in providing consistent cell supply from a validated, pathogen-free source and the generation of cell banks to efficiently supply HLA matched donations. Based on figures from other iPSC regenerative medicine licensing deals, the ROI is expected to be at least 10 fold. The novel platelet production process will have therefore wider benefits, providing job opportunities and revenue to the UK economy.
The concept of generating platelets in vitro from a renewable source of stem cells (in this case human pluripotent stem cells, iPSCs) is therefore attractive: 1. guaranteed supply without donor dependence; 2. matching product to patient: 50% of the demand for HLA type I matching amongst the UK population can potentially be covered by 3 cell lines homozygous for one "common" HLA haplotypes and 3. reduction of the risk of transmission of infection. The potential clinical benefit to the NHS and patients of in vitro produced platelets is therefore clear. After the project end, the process will be translated to GMP manufacture (supported by the Cell Therapy Catapult and NHSBT infrastructure) and first-in-man clinical studies on the Cambridge Biomedical Campus where the NHSBT and the lead PI already carry out volunteer studies to assess transfusion products. This offers a clear route for clinical adoption by the NHS.
Regenerative medicine is at the forefront of the strategy for biomedical research in the UK, supported by initiatives such as the Regenerative Medicine Platform (co-funded by the MRC). The University of Cambridge has already formed (together with the University of Sheffield) an RMP hub addressing the issue of derivation and quality control of iPSCs for human use. This would have a direct link to the proposed project. Platelets derived from iPSCs are an ideal exemplar tissue to develop iPSC-based technology in as much as platelets are anucleated and can be irradiated prior to administration to patients, removing potential concerns over tumor growth from iPSCs-derived cellular products. The strategy adopted in this project, aiming at recreating the niche necessary for cell maturation by means of recombinant proteins can be applied to other tissues grown in vitro and therefore discoveries made within this project will benefit the scientific community as a whole, in particular in the field of regenerative medicine. To this end the lead PI has already established a collaboration with the UK RMP Biochemistry of the Niche Hub (Prof S Forbes, Edinburgh) through which distribution to other researchers can be carried out effectively.
Finally one has to consider the potential economic aspect of this work beyond healthcare provision. The business opportunity is the development of a robust manufacturing protocol for the generation of platelets from iPSCs. This will constitute new IP for the project partners, protected through patenting. This will be licenced to blood product manufacturers, such as NHSBT. Beyond the UK, the global market for platelet provision is $300m. Our product is expected to obtain a large share of the market due to advantages in providing consistent cell supply from a validated, pathogen-free source and the generation of cell banks to efficiently supply HLA matched donations. Based on figures from other iPSC regenerative medicine licensing deals, the ROI is expected to be at least 10 fold. The novel platelet production process will have therefore wider benefits, providing job opportunities and revenue to the UK economy.
Organisations
- University of Cambridge (Lead Research Organisation)
- UNIVERSITY OF OXFORD (Collaboration)
- National Institute of Health and Medical Research (INSERM) (Collaboration)
- Cell Therapy Catapult (Collaboration)
- University of Pavia (Collaboration)
- NHS National Services Scotland (NSS) (Collaboration)
- Platelet BioGenesis, Inc (Collaboration)
- The Wellcome Trust Sanger Institute (Collaboration)
- University of Bristol (Collaboration)
Publications
Engert A
(2016)
The European Hematology Association Roadmap for European Hematology Research: a consensus document.
in Haematologica
Moreau T
(2016)
Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming.
in Nature communications
Chacón-Fernández P
(2016)
Brain-derived Neurotrophic Factor in Megakaryocytes.
in The Journal of biological chemistry
Simeoni I
(2016)
A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.
in Blood
Crosby A
(2018)
Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2-deficient mice.
in Pulmonary circulation
Description | Biogenesis and bioengineering of human platelets |
Amount | £1,200,000 (GBP) |
Funding ID | 219472/Z/19/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 04/2020 |
End | 04/2025 |
Description | EU Horizon 2020 FET |
Amount | € 4,800,000 (EUR) |
Organisation | European Commission |
Department | Horizon 2020 |
Sector | Public |
Country | European Union (EU) |
Start | 11/2017 |
End | 10/2021 |
Description | Generating platelets in vitro for the clinic: optimisation and added clinical efficacy |
Amount | £474,809 (GBP) |
Funding ID | MR/V005413/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2024 |
Description | MRC Translational award |
Amount | £200,000 (GBP) |
Funding ID | MR/P007813/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 10/2017 |
Description | MRC confidence in concept |
Amount | £70,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2016 |
End | 09/2016 |
Description | SilkPlateket |
Amount | € 2,500,000 (EUR) |
Funding ID | 101058349 |
Organisation | European Commission |
Department | Horizon 2020 |
Sector | Public |
Country | European Union (EU) |
Start | 09/2022 |
End | 09/2025 |
Title | Research data supporting 'Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: enhancing production and purity' |
Description | Platelet transfusions are a key treatment option for a range of life threatening conditions including cancer, chemotherapy and surgery. Efficient ex vivo systems to generate donor independent platelets in clinically relevant numbers could provide a useful substitute. Large quantities of megakaryocytes (MKs) can be produced from human pluripotent stem cells, but in 2D culture the ratio of platelets harvested from MK cells has been limited and restricts production rate. The development of biomaterial cell supports that replicate vital hematopoietic micro-environment cues are one strategy that may increase in vitro platelet production rates from iPS derived Megakaryocyte cells. In this paper, we present the results obtained generating, simulating and using a novel structurally-graded collagen scaffold within a flow bioreactor system seeded with programmed stem cells. Theoretical analysis of porosity using micro-computed tomography analysis and synthetic micro-particle filtration provided a predictive tool to tailor cell distribution throughout the material. When used with MK programmed stem cells the graded scaffolds influenced cell location while maintaining the ability to continuously release metabolically active CD41+ CD42+ functional platelets. This scaffold design and novel fabrication technique offers a significant advance in understanding the influence of scaffold architectures on cell seeding, retention and platelet production. |
Type Of Material | Database/Collection of data |
Year Produced | 2022 |
Provided To Others? | Yes |
URL | https://www.repository.cam.ac.uk/handle/1810/332861 |
Description | Collaboration with Cell Therapy Catapult |
Organisation | Cell Therapy Catapult |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Gap analysis for large scale production of platelets in vitro_we are looking to implement them |
Collaborator Contribution | Gap analysis for large scale production of platelets in vitro_we are looking to implement them |
Impact | DSTL grant application |
Start Year | 2020 |
Description | Collaboration with Platelet Biogenesis |
Organisation | Platelet BioGenesis, Inc |
Country | United States |
Sector | Private |
PI Contribution | Platelet Biogenesis is a company based in Boston which has licensed the MK forward programming technology. We have now a sponsored research agreement that allows us to pursue this work further with the company itself |
Collaborator Contribution | They have contributed to cell line research in our laboratory and are testing our cell lines in the bioreactor in Boston. |
Impact | Successful further funding for Platelet Biogenesis which has allowed them to underwrite a sponsored research agreement with my research group. |
Start Year | 2017 |
Description | Collaborations with Paris and Pavia for the production of platelets in vitro (part of EU grant) |
Organisation | National Institute of Health and Medical Research (INSERM) |
Country | France |
Sector | Academic/University |
PI Contribution | The team in Pavia and Paris are using the pluripotent stem cell lines generated in the Ghevaert group to do disease modelling or platelet production in 3D bioreactors. The latter can be functionalised with recombinant proteins that have been identified and generated in my lab, that can promote platelet release. |
Collaborator Contribution | The team in Pavia is providing the 3D silk-based bioreactors. The team in Paris gives us access to patients cell lines for disease modelling. |
Impact | Successful EU grant application |
Start Year | 2015 |
Description | Collaborations with Paris and Pavia for the production of platelets in vitro (part of EU grant) |
Organisation | University of Pavia |
Country | Italy |
Sector | Academic/University |
PI Contribution | The team in Pavia and Paris are using the pluripotent stem cell lines generated in the Ghevaert group to do disease modelling or platelet production in 3D bioreactors. The latter can be functionalised with recombinant proteins that have been identified and generated in my lab, that can promote platelet release. |
Collaborator Contribution | The team in Pavia is providing the 3D silk-based bioreactors. The team in Paris gives us access to patients cell lines for disease modelling. |
Impact | Successful EU grant application |
Start Year | 2015 |
Description | Ectodomain proteins for MK niche generation |
Organisation | The Wellcome Trust Sanger Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Collaboration with Dr Gavin Wright to apply for MRC funding to generate a library of 400 ectodomain proteins to be screened for candidates that promote platelet formation in vitro. We have developed the cellular screening assay. |
Collaborator Contribution | Dr Wright's group will generate the ectodomain proteins. |
Impact | Preliminary application to MRC well-received. Invited to submit full application November 2013 |
Start Year | 2012 |
Description | Production of universal platelets from iPSC at GMP |
Organisation | NHS National Services Scotland (NSS) |
Department | Scottish National Blood Transfusion Service |
Country | United Kingdom |
Sector | Public |
PI Contribution | Developing an iPSC universal cell line for the production of platelets at GMP |
Collaborator Contribution | Process development and gene editing at GMP |
Impact | Process development and gene editing at GMP |
Start Year | 2020 |
Description | Recombinant proteins to promote red cell enucleation |
Organisation | University of Bristol |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have made a library of 400 ectodomain recombinant proteins. |
Collaborator Contribution | Our partners have identified potential proteins that may drive red cell enucleation. They are going to test our proteins to assess whether they promote red cell enucleation in vitro |
Impact | No output yet |
Start Year | 2016 |
Description | Recombinant proteins to promote red cell enucleation |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have made a library of 400 ectodomain recombinant proteins. |
Collaborator Contribution | Our partners have identified potential proteins that may drive red cell enucleation. They are going to test our proteins to assess whether they promote red cell enucleation in vitro |
Impact | No output yet |
Start Year | 2016 |
Title | RESTORE |
Description | Primary haematopoietic progenitors-derived red cells injected into volunteer to show improvement of recovery and survival compared to donor-derived red cells |
Type | Therapeutic Intervention - Cellular and gene therapies |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2020 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Inform future large scale production of in vitro derived blood cells |
URL | https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002178-38 |
Company Name | Celladvice Ltd |
Description | |
Year Established | 2019 |
Impact | Currently providing expert advice to 4 different companies |
Description | Charity Concert All Saints 2018 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Charity concert at which I and professional musicians performed as well as children of the local drama school. The concept was supported by the Cambridge Stem Cell Institute and the benefits went to Naitbabies.org, a patient organisation supporting patients affected by neonatal alloimmune thrombocytopenia |
Year(s) Of Engagement Activity | 2018 |
Description | Charity concert 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Charity concert in Newmarket for the benefit of the East Anglia Air Ambulance_PhD students and post-doc presented some of their stem cell work in the context of regenerative medicine to the general public who attended the concert |
Year(s) Of Engagement Activity | 2019 |
Description | Charity concert 2022 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Charity concert for the benefit of MON voice, a charity supporting patients with Myeloproliferative disorders. |
Year(s) Of Engagement Activity | 2022 |
Description | DSTL: better blood, better outcome workshop |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | DSTL set up the conference to link academics, medical practitioners and industry with an interest in providing blood products to the front line |
Year(s) Of Engagement Activity | 2022 |
Description | Public Engagement Champion Cambridge Stem Cell Institute |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | I have been nominated as the Public Engagement Champion of the CSCI_in short I am the academic PI supporting the Public Engagement team including chairing regular meetings and shaping strategy and implementation thereof |
Year(s) Of Engagement Activity | 2019,2020 |
Description | Radio and BBC news website interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Media (as a channel to the public) |
Results and Impact | After publication of the Nature Communication paper, we were interviewed by the written press (Daily Mail) radio (BBC radio Cambridgeshire, Radio5 live, Radio4 Today programme) and television (ITV and Cambridge TV) |
Year(s) Of Engagement Activity | 2016 |
Description | THOR invited speaker |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Invited speaker at the THOR conference (acute trauma and haemorrhage) |
Year(s) Of Engagement Activity | 2022 |
Description | Youtube distributed movie on production of blood cells in vitros |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | We asked the general public and patients groups to send us questions about the production of blood cells in vitro. Our replies are presented in the form of a short movie that is available on Youtube: |
Year(s) Of Engagement Activity | 2018 |
URL | https://www.youtube.com/watch?v=TCKP0dn2uHk&t=7s |